A 58-year-old woman mistook her womb cancer symptoms for menopause until her stomach became swollen. Diagnosed with advanced-stage womb cancer, she is ...

Endometrial cancer isn’t talked about much as much as it should be. It’s the most common cancer of the female reproductive ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...

DelveInsight's “Menopause Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding ...

Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Monday, February 17th. Leerink Partnrs analyst M. Goodman now ...

The majority of women with uterine fibroids are asymptomatic, consequently get less clinical attention and fibroid tumors often remain undiagnosed. [23,24] Symptomatic women typically complain ...

We value keeping the Device Guide up to date.

StockNews.com lowered shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from a strong-buy rating to a buy rating ...